Connor, Clark & Lunn Investment Management Ltd. Seagen Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$21.8 Billion
Q1 2024

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$191.51 - $216.16 $96,329 - $108,728	503 Added 3.53%	14,771 $3.13 Million
Q2 2023 Aug 10, 2023	BUY	$187.64 - $206.25 $44,283 - $48,675	236 Added 1.68%	14,268 $2.75 Million
Q1 2023 May 09, 2023	SELL	$127.59 - $203.08 $3.12 Million - $4.96 Million	-24,446 Reduced 63.53%	14,032 $2.84 Million
Q4 2022 Feb 10, 2023	BUY	$117.37 - $139.17 $2.62 Million - $3.11 Million	22,325 Added 138.21%	38,478 $4.94 Million
Q3 2022 Nov 10, 2022	BUY	$135.27 - $180.11 $2.19 Million - $2.91 Million	16,153 New	16,153 $2.21 Million

Q2 2022 Aug 05, 2022	SELL	$108.81 - $179.33 $1.32 Million - $2.18 Million	-12,154 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$119.61 - $157.85 $451,168 - $595,410	3,772 Added 45.0%	12,154 $1.75 Million
Q4 2021 Feb 10, 2022	BUY	$142.57 - $190.86 $59,166 - $79,206	415 Added 5.21%	8,382 $1.3 Million
Q3 2021 Nov 12, 2021	SELL	$142.45 - $169.82 $2.07 Million - $2.47 Million	-14,529 Reduced 64.58%	7,967 $1.35 Million
Q2 2021 Aug 12, 2021	SELL	$135.08 - $161.1 $4.03 Million - $4.8 Million	-29,808 Reduced 56.99%	22,496 $3.55 Million
Q1 2021 May 13, 2021	BUY	$137.51 - $190.8 $2.29 Million - $3.18 Million	16,642 Added 46.67%	52,304 $7.26 Million
Q4 2020 Feb 16, 2021	BUY	$164.63 - $211.93 $5.87 Million - $7.56 Million	35,662 New	35,662 $6.25 Million

Others Institutions Holding SGEN

# of Institutions

Shares Held

1.26M

Call Options Held

23K

Put Options Held

55.2K

View Full List

About Seagen Inc.

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

More about SGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account